Oxford student founds Coronavirus help group

first_imgThe initiative has seen huge popularity, with 400+ volunteers committed in just 24 hours. In Oxford, they hope to partner with local groups including charities and food banks, as well as with colleges. Signups for both volunteers, and those needing the services, are open via their website, and a GoFundMe has also been set up.  Speaking to Cherwell, Filz von Reiterdank emphasised the need for volunteers to follow “the necessary hygiene precautions”. They are providing “hygiene guidelines for specific tasks. For example, for grocery shopping, we’d have a video and textual explanation of the safest way to carry it out”.  Their rules, which volunteers are asked to sign before involvement include: always carrying out tasks with a partner; set hygiene guidelines, such as carrying hand sanitiser and cleaning any items touched (e.g. dog leashes) and taking on tasks solely through representatives for safeguarding purposes.  Website They have reached out to health officials to ensure their rules to volunteers are consistent with current medical advice, and within the UK are working closely with two NHS directors.  Facebook group Frederik Filz von Reiterdank has co-founded Students Against Corona, a student led initiative with the aim of helping vulnerable members of local communities, such as those in isolation, or in high-risk groups.  The initiative is the central point of guidance and contact, and aids individuals in starting their own groups in their local areas; Facebook groups for Oxford, Loughborough and Amsterdam – among numerous others – are already in existence.  An Oxford University student has set up a global initiative to provide food and supplies to those that are self-isolating due to Covid-19.  Filz von Reiterdank stressed that many of the issues with current community led initiatives is the reliance on “individuals helping individuals” – he hopes Students Against Corona can eliminate the potential issues that “could harm people”. He wants to harness the community spirit, but provide the necessary infrastructure and advice for this volunteering effort to be carried out safely.  Oxford specific grouplast_img read more

Peptilogics held preIND meeting with FDA to develop PLG0206 for treating prosthetic

first_imgReviewed by Alina Shrourou, B.Sc. (Editor)Aug 25 2018Peptilogics, a development stage company utilizing its innovative peptide platform to treat multidrug-resistant bacterial infections, today announced it recently held a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for the development of PLG0206 for the treatment of prosthetic joint infections (PJI). PJI is one of the most challenging complications of joint arthroplasty and a serious, life-threatening condition with few effective treatment options.”We are delighted with the outcome of the pre-IND meeting,” said Sanjay Kakkar M.D., Chief Executive Officer of Peptilogics. “This key interaction, in addition to the recent QIDP Designation, establishes a viable development path for PLG0206 through clinical proof of concept in this important and significant area of unmet medical need.” Earlier this year, PLG0206 was granted Qualified Infectious Disease Product (QIDP) designation by the FDA.Related StoriesAntibiotic combination effective against drug-resistant PseudomonasStudy shows link between gut microbiome health and successful joint replacementMultifaceted intervention for acute respiratory infection improves antibiotic-prescribingThe FDA meeting served to reach agreement on the details of the development path for the use of PLG0206 in the treatment of PJI. “Peptilogics greatly appreciates the highly positive feedback we received in our pre-IND meeting with the FDA,” said Jonathan Steckbeck, Founder, President and Chief Scientific Officer. “Their clear guidance confirms our plans and will greatly assist our future IND application.”Since PLG0206 will be administered locally into infected joints, Peptilogics has developed a novel population pharmacokinetic (PK) model to simulate systemic absorption following local administration. Parviz Ghahramani, PhD, PharmD, MSc, MBA, early development and Clinical Pharmacology advisor for Peptilogics, will be presenting a poster titled, “Interspecies Allometric Scaling of pre-clinical Data to Predict Human PK Following intravenous and Open Joint Irrigation of PLG0206 – a Novel Antibacterial Peptide” at the upcoming Ninth American Conference on Pharmacometrics (ACoP9). The conference will be held October 7 – 10, 2018, at the Loews Coronado Bay Resort near San Diego, CA. ACoP is the annual scientific meeting of the International Society of Pharmacometrics (ISoP). “We are excited to present this population PK model, developed for PLG0206 administration,” said Dr. Ghahramani. “This model is the first to predict absorption following local administration and will be a powerful tool in the development of PLG0206.”Source: https://www.peptilogics.com/single-post/2018/08/24/Peptilogics-Completes-Successful-Pre-IND-Meeting-with-the-Food-and-Drug-Administration-FDA-for-PLG0206-in-Prosthetic-Joint-Infections-PJIlast_img read more